Assignment of Cancer Relevance to JAX Cancer Center member grants

Guiding principles to assigning CR to grants:

As a basic cancer center, our overarching goal is uncover novel biological mechanisms that lay the groundwork for advancements in cancer prevention and treatment. Our research grant portfolio reflects this goal. We actively engage with fellow Cancer Centers to amplify the impact of our research, fostering meaningful connections that facilitate the translation of our findings to real-world clinical applications. Our collaborative grants and publications reflect this commitment.

Grants can be assigned 100, 75, 50, 25% cancer relevance by meeting at least one of the stated criteria in the category.  Grants that do not meet any of the criteria below are not cancer relevant.

JAXCC Grant 1, 2 Cancer Relevance Guidelines

100% Funded by NCI or other cancer-focused funding agency.  
A cancer-focused theme is evident in the grant title and/or abstract, regardless of the funding source.
Explores the impact of aging on the host to discover novel mechanisms to catalyze new approaches for cancer prevention and treatment.
 75%  Investigating the effects of aging on diseases that share underlying mechanisms with cancer to catalyze discovery of new approaches to cancer prevention and treatment.
 Focuses on biological systems for which there is evidence of a role in cancer.
 Create novel experimental techniques, model systems (e.g. in vivo, in vitro, and in silico), or other research tools that are applicable to research in aging and cancer.
 Develops education and/or training programs that are applicable to aging and cancer research.
 50%  Non-aging research on diseases that share mechanistic pathways with cancer to catalyze new approaches to reduce cancer risk and/or improve treatment response. 
 Focuses on those diseases or medical conditions that arise as a consequence of cancer treatment to discover new mechanisms to prevent an adverse response. 
 Create novel experimental techniques, model systems (e.g. in vivo, in vitro, and in silico), or other research tools that could readily be adapted for research in aging and cancer.
 Develops education and/or training programs that could readily be adapted to aging and cancer research.
 25%  Focuses on non-cancerous disease or tissue to define new biology with the potential to inform cancer research.
 Create novel experimental techniques, model systems (such as in vivo, in vitro, and in silico), or other research tools with a potential use in aging and cancer research.
 Develops education and/or training programs with a potential use in aging and cancer research.
  1. These guidelines apply to peer-reviewed and non-peer reviewed externally funded awards.
  2. Included peer reviewed mechanisms and sources: DP1, DP2, R00, R01, R03, R15, R18, R21, R24, R25, R33, R35, R37, R41, R42, R50, R55, R56, P01, P20, P30s other than the CCSG, P50, SC1, SC2, U01, U10, U19, U24, U54, U56, UH2, UH3, UG3, T32, K and F series awards and N01s (excluding SEER and other N01s funding materials, services, or research resources). Cancer-relevant research funded by these mechanisms from other NIH Institutes may also be counted towards the minimum, as do cancer-relevant grants and contracts from the peer-reviewed funding sources listed in: https://cancercenters.cancer.gov/documents/PRFundingOrgs508.pdf
    3.